MediciNova, Inc. (MNOV)
5.88 -0.08 (-1.34%)
After hours: 5:24PM EST
Chart Events
Performance Outlook
| Previous Close | 5.79 |
| Open | 5.90 |
| Bid | 5.95 x 1000 |
| Ask | 6.50 x 800 |
| Day's Range | 5.86 - 6.13 |
| 52 Week Range | 2.79 - 13.25 |
| Volume | 381,030 |
| Avg. Volume | 203,617 |
| Market Cap | 267.768M |
| Beta (5Y Monthly) | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
Is MediciNova (MNOV) A Good Stock To Buy Now?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 817 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- Zacks Small Cap Research
MNOV: Intranasal SARS-CoV-2 Vaccine Induces Neutralizing Antibodies in Preclinical Studies…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update SARS-CoV-2 Vaccine Induces Neutralizing Antibodies in Mice On September 23, 2020, MediciNova, Inc. (NASDAQ:MNOV) announced that the company’s SARS-CoV-2 vaccine for COVID-19 elicited serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen of SARS-CoV-2 in mice following intranasal vaccination. The
- Simply Wall St.
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
